1) In late December 2019, a cluster of pneumonia cases of unknown cause was reported in Wuhan, China and was later identified as a new coronavirus (nCovid-19). 2) The virus spread rapidly from person to person and caused a pandemic. Common symptoms included fever, cough, and shortness of breath. 3) By January 2020, the WHO had set up an incident management team and was providing regular updates on the outbreak and risk assessment as cases spread beyond China.

1. nCovid-19- AN INSIDIOUS KILLER
SACHIN KUMAR DUBEY
LECTURER
GAUTHAM COLLEGE OF PHARMACY-32
DEPARTMENT OF PHARMACOLOGY

3. HISTORY OF FIRST REPORT
31 Dec 2019
Wuhan Municipal Health Commission, China, reported a cluster of cases
of pneumonia in Wuhan, Hubei Province. A novel coronavirus was eventually
identified.
1 January 2020
WHO had set up the IMST (Incident Management Support Team) across the three
levels of the organization: headquarters, regional headquarters and country level,
putting the organization on an emergency footing for dealing with the outbreak.
4 January 2020
WHO reported on social media that there was a cluster of pneumonia cases – with
no deaths – in Wuhan, Hubei province.
5 January 2020
WHO published our first Disease Outbreak News on the new virus. This is a flagship
technical publication to the scientific and public health community as well as global
media. It contained a risk assessment and advice, and reported on what China had
told the organization about the status of patients and the public health response on
the cluster of pneumonia cases in Wuhan.

4. INTRODUCTION

6. • JOURNEY OF TRANSMISSION

8. SIGN AND SYMPTOMS

9. nCOVID19 & SEASONAL FLU

10. MECHANISM OF INFECTION

11. EPIDEMIOLOGICAL STATUS

12. nCOVID19-PANDEMIC
Wu and McGoogan reported that, among 72,314 COVID-19 cases reported to the Chinese
Center for disease Control and Prevention (CCDC), 81% were mild (absent or mild pneumonia),
14% were severe (hypoxia, dyspnea, >50% lung involvement within 24-48 hours), 5% were
critical (shock, respiratory failure, multiorgan dysfunction), and 2.3% were fatal.

15. SURVIVAL CRISIS
Currently there are no therapeutic agents licensed and available for novel coronavirus 2019. At
the time of the deliberations, one clinical trial was currently ongoing in China including with
Lopinavir and Ritonavir. Another RCT is being planned to evaluate the safety and efficacy of
Remdesevir. Chinese experts are considering a flexible design that could include additional
study arms if pertinent.

17. SURVIVAL GRAPH

18. HUE AND CRY

21. INDIA & nCOVID19

23. ECONOMIC IMPACT OF CORONAVIRUS19

25. PREVENTION

27. FORMULA OF SOCIAL DISTANCING

28. OTHER HOPES…

29. ONLY SURVIVAL GUIDE FOR NOW

30. SACHIN KUMA DUBEY
LECTURER
GAUTHAM COLLEGE OF PHARMACY
DEPT. OF PHARMACOLOGY
THANK YOU